Guiding the Application of Immunotherapy in Nonsmall Cell Lung Cancer: The Role of Biomarkers
Although immunotherapy has completely transformed the treatment landscape of nonsmall cell lung cancer (NSCLC), its wide application is still limited by the heterogeneity of patient responses, primary and acquired resistance, as well as the management challenges of immune‐related adverse events (irAEs). To achieve prec...